Comparison of the Predictive and Prognostic Significance of Circulating Tumor DNA in Patients with High Risk HER2-negative Breast Cancer

Tumor-informed assessment of molecular residual disease

Kasi PM, Dayyani F, Morris V. Poster presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4108.

Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer ESMP 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response and/or detect disease recurrence earlier.

Sequencing of plasma cfDNA from patients with locally advanced bladder cancer AACR 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response to neoadjuvant therapy.

Presence of Circulating Tumor DNA in Surgically Resected Renal Cell Carcinoma ESMO 2020

Circulating tumor DNA (ctDNA) has emerged as a promising, non-invasive biomarker for preclinical detection and monitoring of various cancers.

Personalized circulating tumor DNA analysis to monitor colorectal cancer AACR 2018

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).

Characterization of Clonal Hematopoiesis of Indeterminate Potential Mutations from Germline

Cancer Care and a Tale of Three Molecular "Genomic" Tests ESHG 2020

Hook N, Wallace J, Zimmermann B, et al. Poster presented at: 2020 European Society of Human Genetics; June 6-9, 2020. Abstract E-P16.04.

Analytical validation of the Signatera RUO Assay AACR 2018

The identification of tumor mutations in circulating cell-free DNA (cfDNA) holds great potential for the noninvasive detection of cancer relapse.

Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer ESMO 2020

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for early prediction of relapse across different tumor types.

Serial Circulating Tumor DNA Analysis for Detection of Residual Disease ESMO 2018

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).

Personalized Serial Circulating Tumor DNA Analysis in High-Risk Early Stage Breast Cancer Patients

Analysis of circulating tumor DNA (ctDNA) offers a minimally invasive approach for monitoring treatment response and resistance to treatment in patients with breast cancer.

Early Detection of Residual Breast Cancer through a Robust, Scalable and Personalized Analysis of Circulating Tumour DNA (ctDNA) Antedates O

The potential utility of circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery and/or adjuvant therapy and to monitor metastatic disease has been demonstrated.

Bespoke Circulating Tumor DNA (ctDNA) Analysis as a Predictive Biomarker in Solid Tumor Patients (pts) Treated with Single Agent Pembrolizum

The advent of ultra-sensitive and specific molecular assays has increased the feasibility of circulating tumor DNA (ctDNA) detection.

AACR 2021: Circulating tumor DNA predicts disease recurrence in ovarian cancer patients

Epithelial ovarian, fallopian tube, and peritoneal cancer (EOC) is the most lethal gynecologic malignancy with a 5-year survival rate of 47%.

AACR 2021: Correlation of variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors

Two metrics are commonly used to quantify tumor-specific variants in cell-free DNA (cfDNA): the variant allele frequency (VAF) and mean tumor molecules (MTM)/mL of plasma.